Pacritinib (puh-CRIT-i-nib) is an oral, once daily, selective tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). JAK2 is implicated in myeloproliferative neoplasms (MPN), leukemia and lymphoma, while FLT3 is a commonly mutated gene found in patients with acute myeloid leukemia (AML) and lymphoma. Pactrinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis and may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia.
PERSIST-1 is a multicenter, randomized, controlled Phase 3 trial comparing the efficacy and safety of pacritinib with that of best available therapy in patients with primary myelofibrosis.Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Now enrolling.
Pacritinib is a potent inhibitor of JAK2 (Janus Associated Kinase) and FLT3 kinase activities.